← The Wire
DTILNasdaq
PRECISION BIOSCIENCES INC
Biological Products, (No Diagnostic Substances) · DE · CIK 1357874
Precision BioSciences develops in vivo gene editing therapies using its proprietary ARCUS platform for sophisticated gene edits
red 8-K · 90d
$157M
Market cap
$7.92
Last close
+8.6%
1D
+11.9%
5D
775K
Volume
Price · last 39 sessions+3.8%
May 4L $6.04 · H $8.34Jun 29
194
Total filings
Jun 16, 2026
Last filing
05/21
Fiscal year end
8-KMaterial Agreement · New Debt / ObligationJun 16, 20268-KReg FD Disclosure · Company UpdateMay 27, 20268-KExecutive Change · Bylaw AmendmentMay 26, 202610-Q10-QMay 5, 20268-KResults of OperationsMay 5, 2026DEFA14ADEFA14AApr 8, 2026DEF 14ADEF 14AApr 8, 20268-KReg FD DisclosureMar 17, 202610-K10-KMar 12, 20268-KResults of OperationsMar 12, 20268-KReg FD Disclosure · Company UpdateFeb 11, 20268-KResults of Operations · Reg FD DisclosureJan 13, 20268-KCompany UpdateNov 12, 2025424B5424B5Nov 12, 20258-KReg FD Disclosure · Company UpdateNov 10, 202510-Q10-QNov 3, 20258-KResults of OperationsNov 3, 20258-KExecutive ChangeSep 2, 202510-Q10-QAug 7, 20258-KResults of OperationsAug 7, 20258-KReg FD Disclosure · Company UpdateAug 6, 20258-KShareholder VoteJun 3, 20258-KResults of Operations · Reg FD DisclosureMay 15, 202510-Q10-QMay 15, 20258-KReg FD DisclosureMay 14, 2025DEFA14ADEFA14AApr 15, 2025DEF 14ADEF 14AApr 15, 2025424B5424B5Mar 26, 202510-K10-KMar 26, 20258-KResults of OperationsMar 26, 20258-KExecutive ChangeMar 7, 20258-KExecutive ChangeJan 29, 20258-KResults of Operations · Company UpdateJan 8, 2025SC 13GPRECISION BIOSCIENCES INCNov 14, 202410-Q10-QNov 4, 20248-KResults of OperationsNov 4, 20248-KResults of Operations · Reg FD DisclosureOct 24, 20248-KExecutive Change · Reg FD DisclosureSep 12, 20248-KReg FD DisclosureSep 3, 202410-Q10-QAug 1, 20248-KResults of OperationsAug 1, 20248-KExecutive Change · Shareholder VoteJun 10, 202410-Q10-QMay 13, 20248-KResults of OperationsMay 13, 20248-KCompany UpdateMay 8, 2024DEFA14ADEFA14AApr 25, 2024DEF 14ADEF 14AApr 25, 20248-KAgreement Terminated · Results of OperationsApr 16, 202410-K10-KMar 27, 20248-KResults of OperationsMar 27, 2024SC 13GSC 13GMar 18, 2024SC 13GSC 13GMar 14, 2024424B5424B5Mar 4, 20248-KCompany UpdateMar 1, 2024424B5424B5Feb 29, 20248-KBylaw AmendmentFeb 13, 2024SC 13GSC 13GFeb 5, 20248-KExecutive ChangeJan 23, 20248-KShareholder VoteJan 19, 2024DEFA14ADEFA14AJan 12, 20248-KMaterial Agreement · Results of OperationsJan 11, 20248-KBylaw AmendmentDec 22, 2023DEFA14ADEFA14ADec 4, 2023DEF 14ADEF 14ADec 4, 202310-Q10-QNov 7, 20238-KResults of OperationsNov 7, 20238-KDelisting NoticeOct 25, 20238-K/AMaterial Agreement · New Debt / ObligationOct 20, 20238-KMaterial AgreementOct 19, 20238-KReg FD Disclosure · Company UpdateSep 12, 20238-KExecutive ChangeSep 7, 20238-K/ACompany UpdateAug 21, 20238-KMaterial Agreement · Acquisition / DispositionAug 16, 20238-KResults of OperationsAug 4, 202310-Q10-QAug 4, 20238-KMaterial Agreement · Company UpdateJul 6, 20238-KReg FD Disclosure · Company UpdateMay 31, 20238-KShareholder VoteMay 9, 202310-Q10-QMay 9, 20238-KResults of OperationsMay 9, 2023
Insider Activity
◆ Cluster Buy · 3 insidersIn the 90 days to Feb 18, 2026: 3 insiders bought $34K · 4 sold $431K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 18, 2026 | Amoroso MichaelPresident and CEO | Sell | 20,559 | $3.84 | $79K |
| Feb 18, 2026 | Kelly John AlexanderChief Financial Officer | Sell | 8,149 | $3.84 | $31K |
| Feb 18, 2026 | Scimeca DarioGeneral Counsel and Secretary | Sell | 4,925 | $3.84 | $19K |
| Feb 18, 2026 | Smith J. JeffersonChief Research Officer | Sell | 4,925 | $3.84 | $19K |
| Jan 22, 2026 | Amoroso MichaelPresident and CEO | Sell | 34,799 | $4.17 | $145K |
| Jan 21, 2026 | Kelly John AlexanderChief Financial Officer | Sell | 15,213 | $4.03 | $61K |
| Jan 21, 2026 | Smith J. JeffersonChief Research Officer | Sell | 10,200 | $4.03 | $41K |
| Jan 21, 2026 | Scimeca DarioGeneral Counsel and Secretary | Sell | 8,854 | $4.03 | $36K |
| Dec 16, 2025 | Germano Geno JDirector | Buy | 3,000 | $4.72 | $14K |
| Dec 16, 2025 | Frankel StanleyDirector | Buy | 2,700 | $4.70 | $13K |
| Dec 15, 2025 | Brown MelindaDirector | Buy | 1,381 | $4.97 | $7K |
| Nov 3, 2025 | Amoroso MichaelPresident and CEO | Sell | 3,409 | $6.49 | $22K |
| Nov 3, 2025 | Kelly John AlexanderChief Financial Officer | Sell | 1,303 | $6.49 | $8K |
| Nov 3, 2025 | Scimeca DarioGeneral Counsel and Secretary | Sell | 665 | $6.49 | $4K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance